3,941 Shares in The Clorox Company $CLX Acquired by Caxton Associates LLP

Key Points

• Caxton Associates LLP acquired a new position in The Clorox Company, purchasing 3,941 shares valued at approximately $580,000 during the 1st quarter of 2023.
• Clorox's recent earnings reported $2.87 EPS, surpassing estimates, with a revenue increase of 4.5% year-over-year, leading to a positive outlook for fiscal year 2026.
• The company announced a quarterly dividend of $1.24, representing a 4.0% yield, reflecting a slight increase from the previous $1.22 dividend.

Caxton Associates LLP bought a new position in shares of The Clorox Company (NYSE:CLX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,941 shares of the company's stock, valued at approximately $580,000.

A number of other hedge funds have also made changes to their positions in the business. Wood Tarver Financial Group LLC acquired a new position in shares of Clorox in the 4th quarter valued at $31,000. GW&K Investment Management LLC grew its position in Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock worth $43,000 after purchasing an additional 208 shares during the last quarter. Roble Belko & Company Inc increased its stake in Clorox by 140.7% in the first quarter. Roble Belko & Company Inc now owns 361 shares of the company's stock valued at $53,000 after purchasing an additional 211 shares during the period. IMA Advisory Services Inc. purchased a new stake in shares of Clorox in the first quarter valued at about $58,000. Finally, Menard Financial Group LLC acquired a new stake in shares of Clorox during the fourth quarter worth about $63,000. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Stock Up 1.3%

Clorox stock traded up $1.60 during midday trading on Wednesday, hitting $126.45. The stock had a trading volume of 165,558 shares, compared to its average volume of 1,658,167. The stock has a market cap of $15.47 billion, a P/E ratio of 19.42, a P/E/G ratio of 0.99 and a beta of 0.52. The business has a fifty day moving average price of $124.22 and a 200 day moving average price of $131.86. The company has a current ratio of 0.84, a quick ratio of 0.57 and a debt-to-equity ratio of 5.15. The Clorox Company has a 12 month low of $116.53 and a 12 month high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping analysts' consensus estimates of $2.24 by $0.63. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The company had revenue of $1.99 billion for the quarter, compared to analysts' expectations of $1.94 billion. During the same period in the prior year, the company earned $1.82 earnings per share. The firm's revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Research analysts predict that The Clorox Company will post 7.15 EPS for the current year.

Clorox Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date is Wednesday, October 22nd. Clorox's dividend payout ratio is currently 76.07%.

Wall Street Analyst Weigh In

CLX has been the topic of a number of recent research reports. Jefferies Financial Group dropped their target price on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. UBS Group dropped their price objective on shares of Clorox from $150.00 to $134.00 and set a "neutral" rating on the stock in a research note on Thursday, July 17th. Barclays reduced their target price on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating for the company in a research note on Tuesday, July 15th. JPMorgan Chase & Co. lifted their price objective on Clorox from $133.00 to $135.00 and gave the company a "neutral" rating in a report on Monday, September 8th. Finally, Morgan Stanley reduced their price target on Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Clorox currently has a consensus rating of "Reduce" and an average target price of $142.18.

Insider Buying and Selling

In related news, COO Eric H. Reynolds sold 15,041 shares of the firm's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the sale, the chief operating officer directly owned 54,221 shares in the company, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.57% of the stock is currently owned by insiders.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.